SAB Biotherapeutics (SAB) announced the appointment of Alexandra Kropotova, M.D., as Chief Medical Officer (CMO), to play a critical role in progressing SAB's proprietary immune and autoimmune disorders pipeline. Dr. Kropotova brings to SAB more than 20 years of experience in all phases of global clinical development, translational medicine and medical affairs. Prior to joining SAB, Dr. Kropotova was the Therapeutic Area Head at Global Specialty R&D at Teva Pharmaceuticals, where she led innovative drug development focused on delivering on a broad portfolio of immunology, respiratory, and immuno-oncology assets spanning from pre-IND to BLA/NDA filing of biologics and complex drug-device combination products.

Prior to her tenure at Teva, Dr. Kropotova served in various roles at Sanofi, including Vice President, Strategy & Strategic Planning Head, North American Medical Affairs; Associate Vice President and subsequently Vice President, Immuno-Inflammation, Global R&D Clinical Development; and Senior Medical Director, Respiratory, Allergy & Anti-Infectives. She served in various roles at Pfizer Inc., most recently as Director & Head of Global Clinical Respiratory and Analgesics. She also serves on the Board of Directors at iBio, a global leader in plant-based biologics manufacturing and development of novel biopharmaceuticals.

Dr. Kropotova received her MBA from Ohio University Graduate School of Business in Athens, Ohio; and her M.D. in Internal Medicine from the Vladivostok State Medical University in Vladivostok, Russia.